GC
-
Dada Nexus kicks off $281m US IPO roadshow
China’s Dada Nexus, an operator of on-demand retail and delivery platforms, has launched bookbuilding for its up to $280.5m US listing, according to a source familiar with the matter.
02 Jun 2020 -
NetEase launches $2.8bn Hong Kong secondary listing
Online game developer NetEase has begun bookbuilding for its long-awaited Hong Kong secondary offering. The company is aiming to raise around HK$21.6bn ($2.8bn).
02 Jun 2020 -
NetEase readies jumbo HK secondary listing
US-listed internet giant NetEase is set to launch its Hong Kong secondary public offering, after getting the green light from the city’s stock exchange.
01 Jun 2020 -
Legend Biotech sets ball rolling on $369m US IPO
Biopharmaceutical company Legend Biotech Corp has kicked off bookbuilding for its Nasdaq IPO of up to $368.5m, according to a source familiar with the matter.
01 Jun 2020 -
Korea’s Big Hit files for IPO review
South Korean firm Big Hit Entertainment, manager of popular K-pop boy band BTS, has applied for a preliminary review of its IPO with the Korea Exchange.
29 May 2020 -
More Chinese IPOs expected for London as US tensions grow
Chinese companies are likely to consider London as an alternative foreign listing venue, according to sources speaking to GlobalCapital, following a regulatory crackdown in New York and increased political tensions between the US and China.
26 May 2020 -
Yeahka wins top end pricing for HK$1.6bn IPO
Chinese online payments platform Yeahka rode on strong demand from both institutional and retail investors for its Hong Kong IPO, to price the HK$1.64bn ($211.9m) deal at the top of guidance.
26 May 2020 -
Chinese cancer detection firm Burning Rock eyes US IPO
Burning Rock Biotech is planning to float on Nasdaq for as much as $100m.
25 May 2020 -
JD.com, NetEase ready $5bn secondary IPOs in HK
Chinese internet giants JD.com and NetEase are targeting mid-June to launch their respective Hong Kong listings, according to sources familiar with the matter.
25 May 2020 -
SK Biopharma preps Korea’s debut 2020 IPO, eyes $780m
SK Biopharmaceuticals is set to reopen the South Korean IPO market with a W959.3bn ($779.9m) listing, according to a source close to the deal.
21 May 2020
